A Retrospective Data Collection Study in Patients Receiving Dexamethasone Intravitreal Implant (Ozurdex®) for Macular Oedema Due to Retinal Vein Occlusion (RVO)

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Macular Edema

Interventions

DRUG

dexamethasone intravitreal implant 0.7 mg

Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.

Trial Locations (1)

Münster